Kairos Ventures

GuRu Wireless will participate in Apex Defense 2025, showcasing their groundbreaking wireless energy transfer technology. GuRu's innovative platform can keep small, untethered drones airborne indefinitely—transforming intelligence, surveillance, and reconnaissance operations by eliminating the need for frequent battery swaps, recharging, or physical power connections. GuRu Wireless Vice President Richard Weiss will also present at the event's Tech Showcase, offering insights into how GuRu's scalable and fully synchronous wireless energy transfer solutions at 24GHz are addressing critical operational challenges in defense, national security, and public safety. We’re excited to support GuRu Wireless as they continue to redefine what's possible with adaptive, long-range wireless energy solutions. #KairosVentures #GuRuWireless #DefenseInnovation #ApexDefense2025 #WirelessPower

Actuate Therapeutics, Inc. (NASDAQ: ACTU) will present promising new clinical data on their lead drug candidate, elraglusib, at the AACR Annual Meeting 2025 in Chicago. Elraglusib has shown potential as a novel therapy for advanced salivary gland carcinoma, a challenging and rare cancer type with limited treatment options. The upcoming presentation will highlight how elraglusib, in combination with chemotherapy and immunotherapy, is paving the way for improved outcomes in treating advanced salivary gland cancer. Additionally, separate findings will demonstrate the synergy between elraglusib and other investigational compounds, further expanding its therapeutic possibilities. #KairosVentures #ActuateTherapeutics #CancerResearch #AACR2025 #Biotech #ClinicalTrials

Sivers Semiconductors announced a strategic collaboration with O-Net Technologies to integrate their advanced DFB lasers into O-Net’s next-generation optical modules. This partnership will enable AI data centers to scale up and out to millions of GPUs, powering the future of high-speed optical networking. By combining Sivers' cutting-edge laser technology with O-Net's expertise in optical networking, this collaboration is set to reduce power consumption and accelerate the adoption of Co-Packaged Optics (CPO), creating a more energy-efficient solution for AI and network applications. #AI #DataCenters #Networking #Photonics #SiversSemiconductors #KairosVentures

Sivers Semiconductors announced their new partnership with WIN Semiconductor to scale production of their high-performance DFB lasers. These lasers are essential for improving the speed and efficiency of data transmission, particularly in telecommunications and data centers. By working with WIN Semiconductor, Sivers will be able to meet the growing demand for these cutting-edge components. #SiversSemiconductors #KairosVentures #DataInfrastructure #Telecommunications

So, what’s the secret behind the Transwing®, the unique aircraft that the US Navy is investing over $7 million in to fly parts to broken warships? According to PteroDynamics Inc. CEO Matthew Graczyk, it’s all about creating a solution that can get valuable cargo to hard-to-reach places quickly and efficiently, without the need for complex infrastructure. As Graczyk explains, “Something is valuable. It needs to get somewhere that is hard to get to. It has to get there quickly. It's time-sensitive. And people are paying a lot of money today to do that mission.” PteroDynamics' revolutionary Transwing® design has already gained significant attention from the US Navy and beyond. The Navy’s $4.65 million contract expansion brings the total contract value to $7 million, supporting the development of this innovative aircraft that can deliver critical cargo to warships in remote locations with speed and precision. We’re proud to support PteroDynamics as they continue to innovate and disrupt the world of autonomous flight. #DefenseTech #UAS #PteroDynamics #KairosVentures #MilitaryTechnology #AutonomousFlight

We’re excited to share that PteroDynamics Inc. will be exhibiting their innovative Transwing® vertical takeoff and landing (VTOL) unmanned aerial system at Avalon 2025, Australia’s largest international aerospace and defense exposition, from March 25–30. PteroDynamics will showcase how the revolutionary Transwing aircraft uniquely addresses challenging logistics and surveillance missions, particularly in remote regions like Australia and the Indo-Pacific. Additionally, Tim Whitehand, VP of Engineering, will be delivering a session focused on designing effective, cost-efficient VTOL solutions for defense and commercial applications in this strategically important region. #VTOL #UAS #PteroDynamics #KairosVentures #Avalon2025 #Aerospace #Defense #AutonomousFlight #TechInnovation

Linnaeus Therapeutics, Inc. has recently published groundbreaking data on their clinical candidate LNS8801 in Cancer Research Communications. This novel, first-in-class oral therapy targets the G protein-coupled estrogen receptor (GPER), offering new hope for treating cancers like melanoma. The study demonstrates that LNS8801 has potent anticancer effects and identifies a potential genetic biomarker to guide patient selection for personalized treatment. With these promising results, Linnaeus is moving forward with their Phase 1/2 clinical trial, and they plan to launch a randomized, controlled study later this year to test LNS8801 in patients with treatment-refractory melanoma. #LinnaeusTherapeutics #CancerTherapy #Oncology #KairosVentures #CancerResearch

Sivers Semiconductors AB has launched new antenna array products at Mobile World Congress 2025. These solutions, including advanced millimeter-wave antenna arrays and evaluation kits, are a game-changer for SATCOM and 5G applications, enabling customers to innovate faster and seize new opportunities in rapidly growing markets. With this expansion, Sivers continues to demonstrate its leadership in photonics and wireless technologies, offering end-to-end solutions that will help shape the future of these critical industries. #WirelessTechnology #5G #SATCOM #SiversSemiconductors #KairosVentures #Photonics #MobileWorldCongress2025

Clearsense, Inc has announced their new partnership with Summa Health, one of Ohio’s largest integrated healthcare delivery systems. Through this multi-year agreement, Summa Health will leverage Clearsense’s 1Clearsense Platform to streamline and optimize data across multiple applications, making vital patient information more accessible and actionable within clinical workflows. It’s exciting to witness Clearsense help Summa Health improve care coordination, reduce IT costs, and enhance clinical outcomes, all while advancing the future of healthcare data enablement. #HealthcareInnovation #Clearsense #KairosVentures #TechInHealthcare

Actuate Therapeutics, Inc. has successfully completed patient enrollment in the Phase 2 trial of elraglusib in combination with FOLFIRINOX and losartan for untreated metastatic pancreatic adenocarcinoma. This milestone represents significant progress in the development of elraglusib as a potential treatment for one of the most difficult-to-treat cancers. The trial, led by Dr. Colin Weekes at Massachusetts General Hospital, aims to evaluate the safety, tolerability, and progression-free survival of this innovative combination therapy. Early data from this trial has shown promising clinical activity with significant improvements in survival when combined with other therapies. We look forward to the upcoming results and the potential for elraglusib to offer a transformative treatment option for patients with metastatic pancreatic cancer. #CancerResearch #Elraglusib #ActuateTherapeutics #KairosVentures #Biopharma #ClinicalTrials #PancreaticCancer